Treatment strategies for hot flushes

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 7, 2009, Pages 1133-1144

  Shen, Wen ^a   Stearns, Vered ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Gabapentin; Herbal supplements; Hormone therapy; Hot flushes; Menopause; Night sweats; SNRI; SSRI; Vasomotor symptoms

Indexed keywords

CIMICIFUGA RACEMOSA EXTRACT; CITALOPRAM; CONJUGATED ESTROGEN; DESVENLAFAXINE; DYDROGESTERONE PLUS ESTRADIOL; ESCITALOPRAM; ESTRADIOL; ESTRADIOL PLUS LEVONORGESTREL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTRIOL; ESTROGEN; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; FLUOXETINE; GABAPENTIN; GESTAGEN; MEDROXYPROGESTERONE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; MICRONIZED PROGESTERONE; NORETHISTERONE; NORETHISTERONE ACETATE; PAROXETINE; PRASTERONE; PROGESTERONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; TIBOLONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; NORADRENALIN TRANSPORTER; SLC6A2 PROTEIN, HUMAN;

ACNE; ALOPECIA; APPLICATION SITE REACTION; ARTHRALGIA; BREAST TENDERNESS; CIMICIFUGA RACEMOSA; CLINICAL TRIAL; DECREASED APPETITE; DIET SUPPLEMENTATION; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEMALE; FLUID RETENTION; HEADACHE; HEALTH CARE QUALITY; HEART PALPITATION; HIRSUTISM; HOT FLUSH; HUMAN; INSOMNIA; LEUKORRHEA; LOW DRUG DOSE; MASTALGIA; MENOPAUSAL SYNDROME; MENOPAUSE; MENTAL DISEASE; NAUSEA; NIGHT SWEAT; PERIPHERAL EDEMA; RASH; REVIEW; SIDE EFFECT; SOMNOLENCE; SOYBEAN; SYMPTOM; THROMBOEMBOLISM; TOXIC HEPATITIS; VAGINA DISCHARGE; VASOMOTOR DISORDER; WEIGHT GAIN; XEROSTOMIA; ESTROGEN THERAPY; EVIDENCE BASED MEDICINE; METABOLISM; QUALITY OF LIFE;

ESTROGEN REPLACEMENT THERAPY; EVIDENCE-BASED MEDICINE; FEMALE; HOT FLASHES; HUMANS; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; QUALITY OF LIFE; SEROTONIN UPTAKE INHIBITORS;

EID: 67649559803     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560902868217     Document Type: Review

References (109)

1. Williams RE, Kalilani L, Dibenedetti DB, et al. Frequency and severity of vasomotor symptoms among peri- and postmenopausal women in the United States. Climacteric 2008;11(1):32-43
2. Freeman EW, Sherif K. Prevalence of hot flushes and night sweats around the world: a systematic review. Climacteric 2007;10(3):197-214 (Pubitemid 46752443)
3. Freedman RR, Subramanian M. Effects of symptomatic status and the menstrual cycle on hot flash-related thermoregulatory parameters. Menopause 2005;12(2):156-159 (Pubitemid 40464283)
4. Stearns V. Clinical update: new treatments for hot flushes. Lancet 2007;369(9579):2062-2064 (Pubitemid 46935929)
5. Deecher DC. Physiology of thermoregulatory dysfunction and current approaches to the treatment of vasomotor symptoms. Expert Opin Investig Drugs 2005;14(4):435-448 (Pubitemid 40711853)
6. Randolph JF Jr, Sowers M, Bondarenko I, et al. The relationship of longitudinal change in reproductive hormones and vasomotor symptoms during the menopausal transition. J Clin Endocrinol Metab 2005;90(11):6106-6112 (Pubitemid 41606532)
7. Deecher DC, Dorries K. Understanding the pathophysiology of vasomotor symptoms (hot flushes and night sweats) that occur in perimenopause, menopause, and postmenopause life stages. Arch Womens Ment Health 2007;10(6):247-257
8. Nelson HD. Menopause. Lancet 2008;371(9614):760-770
9. Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004(4):CD002978
10. Greendale GA, Reboussin BA, Hogan P, et al. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/ Progestin Interventions Trial. Obstet Gynecol 1998;92(6):982-988 (Pubitemid 28536116)
11. Utian WH, Shoupe D, Bachmann G, et al. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001;75(6):1065-1079 (Pubitemid 32522600)
12. Notelovitz M, Mattox JH. Suppression of vasomotor and vulvovaginal symptoms with continuous oral 17beta-estradiol. Menopause 2000;7(5):310-317 (Pubitemid 30679427)
13. Notelovitz M, Lenihan JP, Mcdermott M, et al. Initial 17beta-estradiol dose for treating vasomotor symptoms. Obstet Gynecol 2000;95(5):726-731 (Pubitemid 30210060)
14. Rebar RW, Trabal J, Mortola J. Low-dose esterified estrogens (0.3 mg/day): long-term and short-term effects on menopausal symptoms and quality of life in postmenopausal women. Climacteric 2000;3(3):176-182 (Pubitemid 30792329)
15. Simon JA, Snabes MC. Menopausal hormone therapy for vasomotor symptoms: balancing the risks and benefits with ultra-low doses of estrogen. Expert Opin Investig Drugs 2007;16(12):2005-2020
16. Ettinger B. Rationale for use of lower estrogen doses for postmenopausal hormone therapy. Maturitas 2007;57(1):81-84 (Pubitemid 46602903)
17. Carranza-Lira S, Gooch AL, Velasco-Diaz G, et al. Low and ultra low-dose estrogen therapy for climacteric symptom control-preliminary report. Int J Fertil Womens Med 2006;51(4):171-175
18. De Franciscis P, Cobellis L, Fornaro F, et al. Low-dose hormone therapy in the perimenopause. Int J Gynaecol Obstet 2007;98(2):138-142 (Pubitemid 47042730)
19. Panay N, Ylikorkala O, Archer DF, et al. Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief. Climacteric 2007;10(2):120-131 (Pubitemid 46482176)
20. Bachmann GA, Schaefers M, Uddin A, Utian WH. Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2007;110(4):771-779 (Pubitemid 47508739)
21. Rowan JP, Simon JA, Speroff L, Ellman H. Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 microg) in women with postmenopausal symptoms: updated analysis of three randomized, controlled trials. Clin Ther 2006;28(6):921-932 (Pubitemid 44081952)
22. Balfour JA, Heel RC. Transdermal estradiol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of menopausal complaints. Drugs 1990;40(4):561-582
23. Cheang A, Sitruk-Ware R, Utian WH. A risk-benefit appraisal of transdermal estradiol therapy. Drug Saf 1993;9(5):365-379 (Pubitemid 23325296)
24. Good WR, John VA, Ramirez M, Higgins JE. Double-masked, multicenter study of an estradiol matrix transdermal delivery system (Alora) versus placebo in postmenopausal women experiencing menopausal symptoms. Alora Study Group. Clin Ther 1996;18(6):1093-1105
25. Utian WH, Burry KA, Archer DF, et al. Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients. The Esclim Study Group. Am J Obstet Gynecol 1999;181(1):71-79 (Pubitemid 29343333)
26. Bacchi-Modena A, Bolis P, Campagnoli C, et al. Efficacy and tolerability of Estraderm MX, a new estradiol matrix patch. Maturitas 1997;27(3):285-292 (Pubitemid 27356261)
27. Speroff L, Whitcomb RW, Kempfert NJ, et al. Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms. Obstet Gynecol 1996;88(4 Pt 1):587-592 (Pubitemid 26326024)
28. Rovati LC, Setnikar I, Genazzani AR. Dose-response efficacy of a new estradiol transdermal matrix patch for 7-day application: a randomized, double-blind, placebo-controlled study. Italian Menopause Research Group. Gynecol Endocrinol 2000;14(4):282-291 (Pubitemid 30783395)
29. de Vrijer B, Snijders MP, Troostwijk AL, et al. Efficacy and tolerability of a new estradiol delivering matrix patch (Estraderm MX) in postmenopausal women. Maturitas 2000;34(1):47-55 (Pubitemid 30015987)
30. Foidart JM, Vervliet J, Buytaert P. Efficacy of sustained-release vaginal oestriol in alleviating urogenital and systemic climacteric complaints. Maturitas 1991;13(2):99-107
31. Vartiainen J, Wahlstrom T, Nilsson CG. Effects and acceptability of a new 17 beta-oestradiol-releasing vaginal ring in the treatment of postmenopausal complaints. Maturitas 1993;17(2):129-137 (Pubitemid 23287567)
32. Utian WH, Archer DF, Bachmann GA, et al. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause 2008;15(4 Pt 1):584-602
33. Bertelli G, Venturini M, Del Mastro L, et al. Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study. Ann Oncol 2002;13(6):883-888 (Pubitemid 34752683)
34. Prior JC, Nielsen JD, Hitchcock CL, et al. Medroxyprogesterone and conjugated oestrogen are equivalent for hot flushes: a 1-year randomized double-blind trial following premenopausal ovariectomy. Clin Sci (Lond) 2007;112(10):517-525 (Pubitemid 46762013)
35. Leonetti HB, Longo S, Anasti JN. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol 1999;94(2):225-228 (Pubitemid 29352866)
36. Paul SM, Purdy RH. Neuroactive steroids. FASEB J 1992;6(6):2311-2322
37. Surrey ES, Judd HL. Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial. J Clin Endocrinol Metab 1992;75(2):558-563
38. Riis BJ, Christiansen C, Johansen JS, Jacobson J. Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists? J Clin Endocrinol Metab 1990;70(4):920-924
39. Akhila V, Pratapkumar. A comparison of transdermal and oral HRT for menopausal symptom control. Int J Fertil Womens Med 2006;51(2):64-69 (Pubitemid 44050269)
40. Vasomotor symptoms. Obstet Gynecol 2004;104(4 Suppl):106S-17S
41. Haney AF, Wild RA. Options for hormone therapy in women who have had a hysterectomy. Menopause 2007;14(3 Pt 2):592-7; quiz 8-9
42. Haimov-kochman R, Barak-glantz E, Ein-mor E, et al. Duration not severity of the climacteric syndrome predicts resumption of hormone therapy after discontinuation: a prospective cohort study. Hum Reprod 2006;21(9):2450-2454 (Pubitemid 44530627)
43. Aslan E, Bagis T, Kilicdag EB, et al. How best is to discontinue postmenopausal hormone therapy: immediate or tapered? Maturitas 2007;56(1):78-83
44. Haimov-Kochman R, Barak-Glantz E, Arbel R, et al. Gradual discontinuation of hormone therapy does not prevent the reappearance of climacteric symptoms: a randomized prospective study. Menopause 2006;13(3):370-376 (Pubitemid 43918196)
45. Grady D, Sawaya GF. Discontinuation of postmenopausal hormone therapy. Am J Med 2005;118(Suppl 12B):163-165 (Pubitemid 43083597)
46. Ness J, Aronow WS, Beck G. Menopausal symptoms after cessation of hormone replacement therapy. Maturitas 2006;53(3):356-361 (Pubitemid 43163072)
47. Liu JH. Therapeutic effects of progestins, androgens, and tibolone for menopausal symptoms. Am J Med 2005;118(Suppl 12B):88-92 (Pubitemid 43083586)
48. Hammar ML, van de Weijer P, Franke HR, et al. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability. BJOG 2007;114(12):1522-1529 (Pubitemid 350077436)
49. Swanson SG, Drosman S, Helmond FA, Stathopoulos VM. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study. Menopause 2006;13(6):917-925 (Pubitemid 44760384)
50. Landgren MB, Bennink HJ, Helmond FA, Engelen S. Dose-response analysis of effects of tibolone on climacteric symptoms. BJOG 2002;109(10):1109-1114 (Pubitemid 35287079)
51. Modelska K, Cummings S. Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab 2002;87(1):16-23 (Pubitemid 34084663)
52. Berendsen HH. The role of serotonin in hot flushes. Maturitas 2000;36(3):155-164 (Pubitemid 30785830)
53. Umland EM. Treatment strategies for reducing the burden of menopause-associated vasomotor symptoms. J Manag Care Pharm 2008;14(3 Suppl):14-19 (Pubitemid 351696178)
54. Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006;295(17):2057-2071 (Pubitemid 44794007)
55. Loprinzi CL, Sloan JA, Stearns V, et al. Newer antidepressants and gabapentin for hot flashes: an individual subject pooled analysis [abstract 9537]. J Clin Oncol 2008;26
56. Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003;289(21):2827-2834 (Pubitemid 37430118)
57. Stearns V, Slack R, Greep N, et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol 2005;23(28):6919-6930 (Pubitemid 46260278)
58. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356(9247):2059-2063 (Pubitemid 32009821)
59. Soares CN, Joffe H, Viguera AC, et al. Paroxetine versus placebo for women in midlife after hormone therapy discontinuation. Am J Med 2008;121(2):159-162 e1 (Pubitemid 351199467)
60. Loprinzi CL, Sloan JA, Perez EA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002;20(6):1578-1583 (Pubitemid 34260538)
61. Soares CN, Arsenio H, Joffe H, et al. Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women: impact on depression, vasomotor symptoms, sleep, and quality of life. Menopause 2006;13(5):780-786 (Pubitemid 44435032)
62. Deecher DC, Beyer CE, Johnston G, et al. Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 2006;318(2):657-665 (Pubitemid 44061240)
63. Barton DL, Loprinzi CL, Atherton P, et al. Phase II evaluation of desipramine for the treatment of hot flashes. Support Cancer Ther 2007;4(4):219-224 (Pubitemid 47606348)
64. Speroff L, Gass M, Constantine G, Olivier S. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2008;111(1):77-87
65. Loprinzi CL, Stearns V, Barton D. Centrally active nonhormonal hot flash therapies. Am J Med 2005;118(Suppl 12B):118-123 (Pubitemid 43083590)
66. Loprinzi CL, Kugler JW, Barton DL, et al. Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5. J Clin Oncol 2007;25(3):308-312 (Pubitemid 350003019)
67. Fugate SE, Church CO. Nonestrogen treatment modalities for vasomotor symptoms associated with menopause. Ann Pharmacother 2004;38(9):1482-1499 (Pubitemid 39100205)
68. Albertazzi P. Noradrenergic and serotonergic modulation to treat vasomotor symptoms. J Br Menopause Soc 2006;12(1):7-11 (Pubitemid 43349416)
69. Rapkin AJ. Vasomotor symptoms in menopause: physiologic condition and central nervous system approaches to treatment. Am J Obstet Gynecol 2007;196(2):97-106 (Pubitemid 46240000)
70. Ladd CO, Newport DJ, Ragan KA, et al. Venlafaxine in the treatment of depressive and vasomotor symptoms in women with perimenopausal depression. Depress Anxiety 2005;22(2):94-97 (Pubitemid 41598045)
71. Stearns V. Serotonergic agents as an alternative to hormonal therapy for the treatment of menopausal vasomotor symptoms. Treat Endocrinol 2006;5(2):83-87
72. Phillips BB, Digmann RR, Beck MG. Hepatitis associated with low-dose venlafaxine for postmenopausal vasomotor symptoms. Ann Pharmacother 2006;40(2):323-327 (Pubitemid 43269866)
73. Butt DA, Lock M, Lewis JE, et al. Gabapentin for the treatment of menopausal hot flashes: a randomized controlled trial. Menopause 2008;15(2):310-318 (Pubitemid 351354993)
74. Daley A, MacArthur C, Mutrie N, Stokes-Lampard H. Exercise for vasomotor menopausal symptoms. Cochrane Database Syst Rev 2007;(4):CD006108 (Pubitemid 351805229)
75. American association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of menopause. Endocr Pract 2006;12(3):315-337
76. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause 2004;11(1):11-33 (Pubitemid 40362196)
77. Greendale GA, Gold EB. Lifestyle factors: are they related to vasomotor symptoms and do they modify the effectiveness or side effects of hormone therapy? Am J Med 2005;118(Suppl 12B):148-154
78. Shrader SP, Ragucci KR. Life after the women's health initiative: evaluation of postmenopausal symptoms and use of alternative therapies after discontinuation of hormone therapy. Pharmacotherapy 2006;26(10):1403-1409 (Pubitemid 44521725)
79. Lasley BL, Santoro N, Randolf JF, et al. The relationship of circulating dehydroepiandrosterone, testosterone, and estradiol to stages of the menopausal transition and ethnicity. J Clin Endocrinol Metab 2002;87(8):3760-3767 (Pubitemid 34879524)
80. Labrie F, Luu-The V, Labrie C, et al. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 2003;24(2):152-182 (Pubitemid 36515283)
81. Bardia A, Thompson S, Atherton PJ, et al. Pilot evaluation of aprepitant for the treatment of hot flashes. Support Cancer Ther 2006;3(4):240-246 (Pubitemid 44521083)
82. Notelovitz M. Hot flashes and androgens: a biological rationale for clinical practice. Mayo Clin Proc 2004;79(4 Suppl):S8-13 (Pubitemid 38401759)
83. Stomati M, Monteleone P, Casarosa E, et al. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause. Gynecol Endocrinol 2000;14(5):342-363 (Pubitemid 30943364)
84. Simon J, Klaiber E, Wiita B, et al. Differential effects of estrogen-androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women. Menopause 1999 Summer;6(2):138-146 (Pubitemid 29266673)
85. Khorram O. Potential therapeutic effects of prescribed and over-the-counter androgens in women. Clin Obstet Gynecol 2001;44(4):880-892 (Pubitemid 33115834)
86. Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994;78(6):1360-1367 (Pubitemid 24181005)
87. Barnhart KT, Freeman E, Grisso JA, et al. The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life. J Clin Endocrinol Metab 1999;84(11):3896-3902 (Pubitemid 30644171)
88. Lethaby AE, Brown J, Marjoribanks J, et al. Phytoestrogens for vasomotor menopausal symptoms. Cochrane Database Syst Rev 2007;(4):CD001395 (Pubitemid 351805334)
89. Faure ED, Chantre P, Mares P. Effects of a standardized soy extract on hot flushes: a multicenter, double-blind, randomized, placebo-controlled study. Menopause 2002;9(5):329-334 (Pubitemid 36701892)
90. Upmalis DH, Lobo R, Bradley L, et al. Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study. Menopause 2000;7(4):236-242 (Pubitemid 30445953)
91. Quella SK, Loprinzi CL, Barton DL, et al. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial. J Clin Oncol 2000;18(5):1068-1074 (Pubitemid 30123785)
92. Han KK, Soares JM Jr, Haidar MA, et al. Benefits of soy isoflavone therapeutic regimen on menopausal symptoms. Obstet Gynecol 2002;99(3):389-394 (Pubitemid 34188398)
93. MacGregor CA, Canney PA, Patterson G, et al. A randomised double-blind controlled trial of oral soy supplements versus placebo for treatment of menopausal symptoms in patients with early breast cancer. Eur J Cancer 2005;41(5):708-714 (Pubitemid 40342553)
94. Nikander E, Kilkkinen A, Metsa-Heikkila M, et al. A randomized placebo-controlled crossover trial with phytoestrogens in treatment of menopause in breast cancer patients. Obstet Gynecol 2003;101(6):1213-1220 (Pubitemid 36694346)
95. Penotti M, Fabio E, Modena AB, et al. Effect of soy-derived isoflavones on hot flushes, endometrial thickness, and the pulsatility index of the uterine and cerebral arteries. Fertil Steril 2003;79(5):1112-1117 (Pubitemid 36547847)
96. Lewis JE, Nickell LA, Thompson LU, et al. A randomized controlled trial of the effect of dietary soy and flaxseed muffins on quality of life and hot flashes during menopause. Menopause 2006;13(4):631-642 (Pubitemid 44079533)
97. Khaodhiar L, Ricciotti HA, Li L, et al. Daidzein-rich isoflavone aglycones are potentially effective in reducing hot flashes in menopausal women. Menopause 2008;15(1):125-132
98. D'Anna R, Cannata ML, Atteritano M, et al. Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in postmenopausal women: a 1-year randomized, double-blind, placebo-controlled study. Menopause 2007;14(4):648-655 (Pubitemid 47051957)
99. Nahas EA, Nahas-Neto J, Orsatti FL, et al. Efficacy and safety of a soy isoflavone extract in postmenopausal women: a randomized, double-blind, and placebo-controlled study. Maturitas 2007;58(3):249-258 (Pubitemid 350103531)
100. Newton KM, Reed SD, LaCroix AZ, et al. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Ann Intern Med 2006;145(12):869-879 (Pubitemid 351639962)
101. Reed SD, Newton KM, LaCroix AZ, et al. Vaginal, endometrial, and reproductive hormone findings: randomized, placebocontrolled trial of black cohosh, multibotanical herbs, and dietary soy for vasomotor symptoms: the Herbal Alternatives for Menopause (HALT) Study. Menopause 2008;15(1):51-58
102. Pockaj BA, Gallagher JG, Loprinzi CL, et al. Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1. J Clin Oncol 2006;24(18):2836-2841 (Pubitemid 46630583)
103. Geller SE, Studee L. Contemporary alternatives to plant estrogens for menopause. Maturitas 2006;55(Suppl 1):S3-13 (Pubitemid 44693074)
104. Treatment of menopausal vasomotor symptoms. Med Lett Drugs Ther 2004;47(1197-1198):98-99
105. NIH State-of-the-Science Conference Statement on management of menopause-related symptoms. NIH Consens State Sci Statements 2005;22(1):1-38
106. Evans ML, Pritts E, Vittinghoff E, et al. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstetrics Gynecol 2005;105(1):161-166 (Pubitemid 40189927)
107. Loprinzi CL, Sloan JA, Perez PA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002;20:1578-1583 (Pubitemid 34260538)
108. Suvanto-Luukkonen E, Koivunen R, Sundstrom H, et al. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study. Menopause 2005;12(1):18-26 (Pubitemid 40204889)
109. Reddy SY, Warner H, Guttuso T Jr, et al. Gabapetin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol 2006;108(1):41-48 (Pubitemid 44336843)